

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**TransThera Sciences (Nanjing), Inc.**  
**藥捷安康(南京)科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock Code: 2617)**

**VOLUNTARY ANNOUNCEMENT**  
**COLLABORATION WITH NEUROCRINE**

This announcement is made by TransThera Sciences (Nanjing), Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that Neurocrine Biosciences, Inc. (NASDAQ: NBIX) (“**Neurocrine**”) and the Company entered into a royalty bearing patent assignment and research collaboration agreement to develop NLRP3 inhibitors, one of the Company’s preclinical assets, for multiple diseases (the “**Agreement**”).

According to the Agreement, Neurocrine is granted an exclusive right in ex-Greater China region to develop, manufacture, and commercialize NLRP3 inhibitors from TransThera’s NLRP3 portfolio, and the Company has rights to develop, manufacture and commercialize the NLRP3 portfolio in Greater China region (Mainland, HK, Taiwan, Macao). Under the Agreement, the Company will be entitled to an upfront payment and, depending on the development and commercialization progress of Neurocrine, the Company may receive further milestone payments associated with research and development milestones and sales milestones, providing the Agreement with a total potential value of up to US\$881.5 million. The Agreement further includes a research collaboration between the parties to further broaden NLRP3 technology.

Warning under Rule 18A.08(3) of the Listing Rules: There is no assurance that the relevant products will ultimately be successfully developed and marketed.

By order of the Board  
**TransThera Sciences (Nanjing), Inc.**  
**藥捷安康(南京)科技股份有限公司**  
**Dr. Frank Wu**  
*Chairman and Chief Executive Officer*

Hong Kong, November 3, 2025

*As at the date of this announcement, the Board comprises: (i) Dr. Frank Wu and Mr. Wu Di as executive directors; (ii) Ms. Jia Zhongxin and Dr. Yi Hua as non-executive directors; and (iii) Mr. Li Shu Pai, Ms. Chui Hoi Yam and Ms. Zheng Zhelan as independent non-executive directors.*